Literature DB >> 9851507

Haemorrhagic activity of neotropical rattlesnake (Crotalus vegrandis Klauber, 1941) venom.

A Rodriguez-Acosta1, I Aguilar, M Giron, V Rodriguez-Pulido.   

Abstract

In this work we have demonstrated for the first time in any Venezuelan Crotalus, haemorrhagic activities that are present in the Neotropical Uracoan rattlesnake (Crotalus vegrandis) venom. This venom has been little studied, perhaps because the snake is restricted to a small habitat located in the dry savannahs of northeastern Venezuela. In our experiments Crotalus vegrandis venom caused a very evident haemorrhagic area consisting of approximately 2/3 diameter of the area caused by a positive control Bothrops lanceolatus venom. Crotalus vegrandis venom affects blood coagulation and causes intense haemorrhages. It does not clot fibrinogen, therefore it has neither thrombin-like activity which transforms fibrinogen to fibrin nor procoagulant enzymatic function which produces thrombin. On the other hand, it degrades fibrinogen making it incoagulable to thrombin. The venom, when injected in the animals, resulted in a high increase of the Partial Time of Thromboplastin (PTT) tests. It is interesting to observe that the haemorrhagic capacity in the Crotalus genus (widely distributed in the American continent) increases from south to the north, being present in North American Crotalus, a venom with wide haemorrhagic activities, and almost non-existent in most of the South American Crotalus species and subspecies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851507     DOI: 10.1002/(sici)1522-7189(199802)6:1<15::aid-nt2>3.0.co;2-s

Source DB:  PubMed          Journal:  Nat Toxins        ISSN: 1056-9014


  1 in total

1.  Structural and biological characterization of two crotamine isoforms IV-2 and IV-3 isolated from the Crotalus durissus cumanensis venom.

Authors:  Luis Alberto Ponce-Soto; Daniel Martins-de-Souza; Daniel Martins; José Camillo Novello; Sergio Marangoni
Journal:  Protein J       Date:  2007-12       Impact factor: 2.371

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.